OpenAI Acquires Drug Development Platform Orchestra Bio

OpenAI has announced the acquisition of the Orchestra Bio platform, which helps biopharma teams coordinate complex drug development processes. With this move, Orchestra's team and technology are being integrated into Rosalind, OpenAI's suite of AI models and tools for life sciences research.

While it is noted that discovering a new drug from target discovery to regulatory approval in the United States takes an average of 10 to 15 years, it was stated that teams often have to manage programs between internal departments and external partners using disconnected systems. OpenAI noted that we are entering an era where AI can take on these specialized tasks and complex workflows.

While Rosalind offers AI models and tools to researchers, GPT-Rosalind helps reason through questions in biology and chemistry, and Rosalind Workbench brings these capabilities together with scientific tools and data for analyzing results and planning experiments. Orchestra Bio, on the other hand, offers a platform established with a team experienced in biotechnology, software, and AI to coordinate drug development processes.

On the Orchestra Bio platform, humans and AI agents work together to advance drug programs. Agents take on the tracking and monitoring of studies, giving scientists the ability to guide, make decisions, and address issues without delays. The statement emphasized that partnerships with organizations such as Novo Nordisk and Moderna also contribute to accelerating research.